These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1093 related items for PubMed ID: 25586681

  • 1. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD, Han JH, Rock C, Harris AD, Lautenbach E, Hsu AJ, Avdic E, Cosgrove SE, Antibacterial Resistance Leadership Group.
    Clin Infect Dis; 2015 May 01; 60(9):1319-25. PubMed ID: 25586681
    [Abstract] [Full Text] [Related]

  • 2. Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ng TM, Khong WX, Harris PN, De PP, Chow A, Tambyah PA, Lye DC.
    PLoS One; 2016 May 01; 11(4):e0153696. PubMed ID: 27104951
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Appropriate non-carbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study.
    Ko JH, Lee NR, Joo EJ, Moon SY, Choi JK, Park DA, Peck KR.
    Eur J Clin Microbiol Infect Dis; 2018 Feb 01; 37(2):305-311. PubMed ID: 29177611
    [Abstract] [Full Text] [Related]

  • 6. Carbapenems Versus Piperacillin-Tazobactam for Bloodstream Infections of Nonurinary Source Caused by Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae.
    Ofer-Friedman H, Shefler C, Sharma S, Tirosh A, Tal-Jasper R, Kandipalli D, Sharma S, Bathina P, Kaplansky T, Maskit M, Azouri T, Lazarovitch T, Zaidenstein R, Kaye KS, Marchaim D.
    Infect Control Hosp Epidemiol; 2015 Aug 01; 36(8):981-5. PubMed ID: 25990361
    [Abstract] [Full Text] [Related]

  • 7. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM, Askin G, Christos P.
    Int J Antimicrob Agents; 2018 Nov 01; 52(5):554-570. PubMed ID: 30081138
    [Abstract] [Full Text] [Related]

  • 8. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
    Han SB, Jung SW, Bae EY, Lee JW, Lee DG, Chung NG, Jeong DC, Cho B, Kang JH, Kim HK, Park YJ.
    Microb Drug Resist; 2015 Apr 01; 21(2):244-51. PubMed ID: 25398058
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.
    Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, Alenazi TH, Arabi Y, Falcone M, Bassetti M, Righi E, Rogers BA, Kanj S, Bhally H, Iredell J, Mendelson M, Boyles TH, Looke D, Miyakis S, Walls G, Al Khamis M, Zikri A, Crowe A, Ingram P, Daneman N, Griffin P, Athan E, Lorenc P, Baker P, Roberts L, Beatson SA, Peleg AY, Harris-Brown T, Paterson DL, MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network (ASID-CRN).
    JAMA; 2018 Sep 11; 320(10):984-994. PubMed ID: 30208454
    [Abstract] [Full Text] [Related]

  • 16. The Use of Noncarbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase Infections.
    Tamma PD, Rodriguez-Bano J.
    Clin Infect Dis; 2017 Apr 01; 64(7):972-980. PubMed ID: 28362938
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum β-lactamase-producing Escherichia coli.
    Yoon YK, Kim JH, Sohn JW, Yang KS, Kim MJ.
    Int J Antimicrob Agents; 2017 Apr 01; 49(4):410-415. PubMed ID: 28263710
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 55.